Table 1.
Incidences and sites of C2 metastasis/recurrence after treatment
| Adjuvant treatment | Regional lymph nodes | Resection site | Lung and/or salivary gland |
|---|---|---|---|
| Control IgG | |||
| Experiment 1 | 9/9 (100) | 6/9 (67) | 4/9 (44) |
| Experiment 2 | 14/15 (93) | 3/15 (20) | 8/15 (53) |
| Experiment 3 | 15/15 (100) | 0/15 (0) | 9/15 (60) |
| CTLA-4 blockade | |||
| Experiment 1 | 4/9 (44) | 2/9 (22) | 2/9 (22) |
| Experiment 2 | 5/14 (36) | 1/14 (7) | 4/14 (29) |
| Experiment 3 | 7/15 (47) | 0/15 (0) | 3/15 (20) |
After resection of C2 primary tumors and adjunctive treatment with either control IgG or anti-CTLA-4 (CTLA-4 blockade), mice were monitored for ≥150 days for overt tumor outgrowth at regional lymph node sites (axillary or anterior cervical nodes) or the tumor resection site. When aggregate tumor dimensions achieved 250 mm2, mice were killed, and regional lymph nodes, lungs, and salivary glands were harvested. Lungs and salivary glands were fixed and stained by routine H&E to assess the presence of distant microscopic metastases to these organs. Data are the number of mice that had C2 metastases (reported according to site of failure) over the total number of mice in the treatment cohort. Percentages of mice with metastases (reported according to site of failure) are given in parentheses.